UKAD 2016 UKAD vs Shila Panjavi
March 2, 2017
In July 2016 United Kingdom Anti-Doping (UKAD) has reported an anti-doping rule violation against the Athlete Shila Panjavi after her sample tested positive for the prohibited substance stanozolol. After notification a provisional suspension was ordered. The Athlete filed a statement in her defence and she was heard for the National Anti-Doping Panel.
The Athlete admitted the violation and stated that she had acquired approximately 100 free samples of supplements and she ingested approximately 20 of those supplements. She also acquired vitamin B and vitamin E vials from Iran when she visited and she injected herself with these vitamins. She stated that previously on her trip in Iran in 2015 she suffered from a foot swelling which was treated by a local Kurdish doctor with prescribed stanozolol. In April 2016, two months before the sample collection, she suffered again in Iran from a foot swelling. Assisted by her father to translate she revisited the Kurdish doctor and the same medication was prescribed. Here she realized that stanozolol was prescribed and that it was a prohibited substance.
However Professor Cowan of the WADA accredited laboratory in London stated that the Athlete’s explanation is not consistent with the test results from her samples collected in June 2016.
Apart from Prof. Cowan’s evidence the Panel is not satisfied that the Athlete’s explanation was true and it leads the Panel to reject the Athlete’s explanantion for the presence of stanozolol in her system.
In addition UKAD reported that during the provisional suspension the Athlete was training in the weightling club owned by her father. The Panel considered the evidence in this matter and concludes, by a small margin, that the allegation of the Athlete’s breach of the provisional suspension is not proved.
Therefore the National Anti-Doping Panel decides on 2 March 2017 to impose a 4 year period of ineligibility on the Athlete starting on the date of the provisional suspension, i.e. on 8 July 2016.
